Hemodynamics for experimental groups at baseline, 15 min of ischemia, and 2 h of reperfusion Drug doses are in parentheses in milligrams per kilogram.
n | Baseline | 15-min Ischemia | 2-h Reperfusion | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR | MAP | RPP | HR | MAP | RPP | HR | MAP | RPP | ||||||||
| V (95% EtOH) | 6 | 340 ± 16 | 120 ± 9 | 50 ± 5 | 340 ± 15 | 112 ± 11 | 44 ± 4 | 322 ± 7 | 84 ± 13 | 34 ± 4 | ||||||
| MOR (0.1) | 6 | 375 ± 13 | 132 ± 7 | 58 ± 3 | 390 ± 8 | 111 ± 7 | 49 ± 3 | 318 ± 17 | 91 ± 7 | 35 ± 3 | ||||||
| MOR (0.2) | 6 | 337 ± 16 | 110 ± 4 | 43 ± 3 | 353 ± 11 | 104 ± 9 | 41 ± 4 | 327 ± 20 | 91 ± 10 | 36 ± 5 | ||||||
| MOR (0.3) | 6 | 343 ± 12 | 123 ± 5 | 49 ± 2 | 365 ± 12 | 106 ± 3 | 44 ± 2 | 305 ± 15 | 85 ± 5 | 32 ± 2 | ||||||
| IBU (0.6) | 6 | 340 ± 19 | 115 ± 7 | 46 ± 4 | 368 ± 20 | 110 ± 6 | 45 ± 2 | 330 ± 16 | 86 ± 11 | 34 ± 3 | ||||||
| IBU (1) | 6 | 340 ± 6 | 119 ± 3 | 48 ± 1 | 358 ± 8 | 106 ± 7 | 43 ± 3 | 343 ± 7 | 90 ± 13 | 36 ± 5 | ||||||
| IBU (3) | 6 | 335 ± 16 | 99 ± 8 | 41 ± 4 | 355 ± 11 | 98 ± 10 | 41 ± 5 | 305 ± 11 | 87 ± 9 | 33 ± 3 | ||||||
| ASA (0.6) | 6 | 363 ± 23 | 118 ± 16 | 51 ± 9 | 387 ± 18 | 121 ± 13 | 53 ± 7 | 340 ± 25 | 97 ± 14 | 40 ± 6 | ||||||
| ASA (1) | 6 | 333 ± 15 | 112 ± 10 | 46 ± 5 | 356 ± 13 | 106 ± 10 | 44 ± 4 | 313 ± 13 | 86 ± 5 | 34 ± 3 | ||||||
| ASA (3) | 6 | 348 ± 8 | 120 ± 3 | 49 ± 2 | 365 ± 12 | 113 ± 6 | 47 ± 3 | 325 ± 14 | 94 ± 4 | 36 ± 3 | ||||||
| V (95% EtOH) at reperfusion | 6 | 350 ± 19 | 121 ± 8 | 51 ± 5 | 378 ± 15 | 103 ± 11 | 48 ± 4 | 315 ± 14 | 83 ± 14 | 37 ± 4 | ||||||
| MOR (0.3) at reperfusion | 6 | 378 ± 10 | 134 ± 5 | 59 ± 3 | 381 ± 4 | 119 ± 7 | 52 ± 3 | 335 ± 9 | 82 ± 5 | 35 ± 2 | ||||||
| IBU (3) at reperfusion | 6 | 380 ± 9 | 130 ± 4 | 57 ± 3 | 381 ± 13 | 114 ± 8 | 50 ± 4 | 313 ± 15 | 93 ± 11 | 37 ± 4 | ||||||
| ASA (3) at reperfusion | 6 | 357 ± 8 | 124 ± 4 | 53 ± 2 | 380 ± 8 | 111 ± 6 | 49 ± 3 | 325 ± 8 | 69 ± 6 | 31 ± 2 | ||||||
| ASA (1) + MOR (0.3) | 6 | 350 ± 6 | 129 ± 5 | 53 ± 3 | 360 ± 5 | 123 ± 6 | 50 ± 3 | 307 ± 8 | 77 ± 6 | 31 ± 2 | ||||||
| ASA (3) + MOR (0.3) | 6 | 352 ± 7 | 128 ± 4 | 53 ± 2 | 353 ± 8 | 121 ± 5 | 49 ± 2 | 312 ± 8 | 87 ± 4 | 35 ± 2 | ||||||
| IBU (3) + MOR (0.3) | 6 | 340 ± 9 | 126 ± 6 | 50 ± 3 | 352 ± 12 | 116 ± 6 | 45 ± 3 | 290 ± 12 | 83 ± 6 | 29 ± 3 | ||||||
| IBU (0.6) + MOR (0.2) | 8 | 361 ± 6 | 111 ± 5 | 48 ± 2 | 376 ± 7 | 106 ± 5 | 46 ± 3 | 313 ± 8 | 79 ± 5 | 31 ± 2 | ||||||
| ASA (0.6) + MOR (0.2) | 6 | 358 ± 10 | 114 ± 6 | 48 ± 3 | 375 ± 7 | 113 ± 6 | 47 ± 3 | 322 ± 10 | 85 ± 8 | 34 ± 3 | ||||||
| V (DMSO) | 6 | 347 ± 14 | 119 ± 9 | 49 ± 4 | 358 ± 11 | 116 ± 7 | 47 ± 2 | 328 ± 11 | 90 ± 12 | 37 ± 5 | ||||||
| BAC (3) + MOR (0.3) | 6 | 348 ± 11 | 110 ± 6 | 46 ± 3 | 357 ± 14 | 104 ± 11 | 45 ± 7 | 318 ± 14 | 71 ± 4 | 30 ± 2 | ||||||
| BAC (3) + BU (3) | 6 | 345 ± 8 | 122 ± 9 | 50 ± 4 | 350 ± 10 | 133 ± 12 | 53 ± 6 | 333 ± 10 | 91 ± 10 | 38 ± 4 | ||||||
| BAC (3) + BU (0.6) + MOR (0.2) | 8 | 356 ± 10 | 123 ± 4 | 51 ± 3 | 371 ± 11 | 125 ± 7 | 52 ± 4 | 335 ± 13 | 80 ± 6 | 34 ± 3 | ||||||
| BAC (3) | 6 | 355 ± 11 | 129 ± 6 | 53 ± 3 | 346 ± 12 | 106 ± 12 | 42 ± 5 | 327 ± 14 | 76 ± 7 | 33 ± 2 | ||||||
| 12(S)-HETE (0.015) | 6 | 385 ± 11 | 129 ± 4 | 59 ± 2 | 395 ± 13 | 116 ± 3 | 53 ± 2 | 347 ± 13 | 74 ± 4 | 35 ± 2 | ||||||
ASA, aspirin; BAC, baicalein; HR, heart rate; IBU, ibuprofen; MAP, mean arterial pressure; MOR, morphine; RPP, rate pressure product.